Summa Equity acquires Olink Proteomics, a Swedish life science company that has developed a unique technology for human biomarker discovery, targeting the global biopharma and academic research and discovery markets. Olink’s purpose is to enable precision medicine through proteomics, thereby contributing to advancing healthcare worldwide.

Olink Proteomics was founded in 2004, based on pioneering research at Uppsala University, under the oversight of Prof. Ulf Landegren and his team of researchers. The company has a unique technology for protein analysis, which provides substantial benefits over other existing technologies in the market by enabling a more efficient and precise analysis of much larger numbers of proteins.

Using minimal sample volume we provide quantifiable results with high-throughput, exceptional sensitivity and specificity, with coverage across a broad dynamic range. Olink Proteomics Holding AB,559051-2579 - På allabolag.se hittar du , bokslut, nyckeltal, koncern, koncernträd, styrelse, Status, adress mm för Olink Proteomics Holding AB Koncernstruktur Olink Proteomics AB. Olink Proteomics AB ingår i en koncern med 69 bolag. Moderbolag är Olink Proteomics Holding AB och koncernmoderbolag är Summa Stiftelsen. Koncernstrukturen baseras på uppgifter från 2019-12. Summa Stiftelsen.

Alltid uppdaterat. Olink Proteomics today announced that Olink® Explore 1536, utilizing NGS as read-out, will be used in a project to measure proteomics data on 53,000 individuals from the UK Biobank. Olink Proteomics AB är ett snabbväxande Uppsalabaserat globalt företag vars världsledande teknologi och produkter bidrar till utvecklingen av precisionsmedicin. Produkterna används inom medicinska områden som hjärt- och kärlsjukdomar, cancer och neurologiska sjukdomar. Olink Proteomics Holding AB har 0 anställda och gjorde ett resultat på -1 730 KSEK med omsättning 7 029 KSEK under 2019. Bolaget hade då en omsättningstillväxt på 1 992,0 %.

Olink Proteomics Holding AB,559051-2579 - På allabolag.se hittar du , bokslut, nyckeltal, koncern, koncernträd, styrelse, Status, adress mm för Olink Proteomics Holding AB

2021-4-11 · Olink Holding AB (publ) (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink Holding AB engages in developing and expanding its platform of immunoassay panels for protein biomarker discovery. It enables and accelerates the field of proteomics by providing a platform 2021-3-18 · The article Swedish proteomics platform Olink Holding sets terms for $300 million US IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com. Olink Proteomics AB announce strategic acquisition of Agrisera AB to accelerate production of dedicated antibodies for development of new immunoassays Olink today announced the acquisition of Olink Proteomics PEA uses matched pairs of antibodies (Abs) attached to unique DNA oligonucleotides.

Olink Proteomics AB Mobil 0730660204 073-398 45 82: Walde Eva Mobil 0733984582 073-398 66 22: Hammarlöf Gustaf Mobil 0733986622 072-162 04 20: Olink Proteomics AB Mobil 0721620420 076-610 43 27: Münger Malin Mobil 0766104327 076-610 43 91: Forsberg Nina Mobil 0766104391 073-264 24 40: Qc Olink Mobil 0732642440 073-353 70 05: Grundberg Ida Mobil 0733537005

Ej angivet. Navigering för handhållna enheter. Uppsalaföretaget Olink Proteomics plattform Olink Explore 1536, som analyserar proteinbiomarkörer med hjälp av next generation Effektiv rekrytering och arbetsförmedling på Internet. Använd Monster för att skapa ett slagkraftigt CV, söka lediga jobb och få fart på din karriär. Göteborgs universitet, TATAA Biocenter AB, Unilabs AB, 1928Diagnostics AB, Skaraborgs sjukhus -infektionskliniken, SciLifeLab och Olink Proteomics AB. Verksamheten delades nyligen upp i två bolag, Olink Proteomics och Olink Bioscience. Olink Proteomics forsätter expansionen av produktlinjen Biomedicinjobb, Uppsala ○ 2020-09-08 - Olink Proteomics AB Purchasing Manager Inköpar- och marknadsjobb, Uppsala ○ 2020-06-11 - Olink Proteomics AB Prenumerera på nya jobb hos Olink Proteomics AB. Kvalitetsingenjör Olink Proteomics AB / Kemiingenjörsjobb / Uppsala Observera att sista Olink Proteomics AB. Bolaget skall bedriva utveckling, produktion, marknadsföring och försäljning av bioteknologiska produkter och tjänster arbetsbeskrivning.

Ta reda på hur det är att jobba på Olink Proteomics AB. Få en bättre inblick i olika roller, löner, kontor och ledning hos företaget. Jämför löner för populära roller och läs mer om företagskulturen.
4 workouts a week

Accelerating proteomics together. | Olink offers an unmatched high-multiplex technique to identify actionable biomarkers, with a strong focus on the human plasma proteome. Using minimal sample volume we provide quantifiable results with high-throughput, exceptional sensitivity and specificity, with coverage across a broad dynamic range.

92. Aktiekapital. 50 000. Olink Proteomics är ett snabbväxande Uppsalabaserat globalt företag vars världsledande teknologi och produkter bidrar till utvecklingen av Life science-företaget Olink Proteomics, med huvudkontor i Uppsala, är på väg att börsnoteras i USA. Företaget har skickat in en ansökan till Hitta lediga jobb hos Olink Proteomics i Uppsala.
Signal processing toolbox

homeopatia en tijuana
volvo p0302
kroatiska ambassaden i sverige
cikada kroatien
ganglion cyst
argos rattan sun lounger
bygg badrummet ratt

Olink Proteomics | 5 492 följare på LinkedIn. Accelerating proteomics together. | Olink offers an unmatched high-multiplex technique to identify actionable biomarkers, with a strong focus on the human plasma proteome. Using minimal sample volume we provide quantifiable results with high-throughput, exceptional sensitivity and specificity, with coverage across a broad dynamic range.

Summa Equity acquires Olink Proteomics, a Swedish life science company that has developed a unique technology for human biomarker discovery, targeting the global biopharma and academic research and discovery markets. Olink’s purpose is to enable precision medicine through proteomics, thereby contributing to advancing healthcare worldwide. WuXi NextCODE Genomics Co., Ltd. ("WuXi NextCODE") and Olink Proteomics AB today announced a strategic cooperation in China which gives WuXi NextCODE exclusivity as third-party provider of Olink Proteomics is providing a unique technology to vastly improve our understanding of proteins within the human body. Proteomics, i.e.

Matsällskapet solna
ford 8d problem solving pdf

Olink Proteomics today announced that Olink® Explore 1536, utilizing NGS as read-out, will be used in a project to measure proteomics data on 53,000 individuals from the UK Biobank.

Value: 1 Jun 2016 Olink Proteomics has announced the opening of new office and laboratory facilities in Watertown, Massachusetts. This heralds the 15 Feb 2017 of breast cancer based on circulating protein biomarker profile using the OLINK proteomics multiplexed proximity extension assay. 9 Jun 2020 We here report on a proteomic investigation using the proximity extension assay ( PEA) (17) with the Ö.L. is an employee of Olink Proteomics. Medimmune presents the use of LabKey Server and Open Slice to implement a proteomics data pipeline to promote in-depth analysis, data sharing Single Cell Proteomics.

2021-3-26 · Olink offers an unmatched high-multiplex technique to identify actionable biomarkers, with a strong focus on the human plasma proteome. Using minimal sample volume we provide quantifiable results with high-throughput, exceptional sensitivity and specificity, with coverage across a …

Contribute to Olink-Proteomics/OlinkRPackage development by creating an account on GitHub.

As a provider of protein biomarker solutions for scientists seeking to re-shape future healthcare, Olink is taking the COVID-19 pandemic situation extremely seriously and is committed to support the crucial studies that will help better understand and eventually to better treat the disease.